Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies

Main Article Content

A Blauvelt
C Paul
P van de Kerkhof
R B Warren
A B Gottlieb
R G Langley
F Brock
C Arendt
M Boehnlein
M Lebwohl
K Reich

Keywords

Psoriasis, Biologics, Certolizumab, safety

Abstract

Abstract not available.

References

1. Certolizumab Pegol Prescribing Information. Available at www.accessdata.fda.gov/scripts/cder/daf/index.cfm

2. Certolizumab Pegol Summary of Product Characteristics. Available at www.ema.europa.eu/en/
medicines/human/EPAR/cimzia-0;

3. Blauvelt A et al. JEADV 2019;33(suppl 3):21–2; 4. Gisondi P et al. Int J Mol Sci 2017;18:2427.